Results from a macaque study showed that although implants that slow-released a low dose of islatravir protected animals against rectal exposure to wild-type SHIV, it failed to protect against SHIV with the M184V mutation.
This study is important because although islatravir is no longer being developed as PrEP, it is structurally very similar to the investigational NRTTI MK-8527 which is now entering phase 3 studies as a once-monthly oral formulation of PrEP.
Source : HIV i-Base
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.